Dr Lal Pathlabs Ltd

Dr Lal Pathlabs Ltd

₹ 3,026 -0.50%
21 Nov - close price
About

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]

Key Points

About[1]
It is the largest diagnostics chain with a PAN India presence The company has 70+ yrs of experience in the field of diagnostics. The company has serviced 122 Mn+ patients
in the last 5 years.

  • Market Cap 25,292 Cr.
  • Current Price 3,026
  • High / Low 3,654 / 1,943
  • Stock P/E 63.0
  • Book Value 240
  • Dividend Yield 0.79 %
  • ROCE 25.2 %
  • ROE 20.4 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company has been maintaining a healthy dividend payout of 30.6%

Cons

  • Stock is trading at 12.6 times its book value
  • Promoter holding has decreased over last quarter: -0.68%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
498 497 486 503 534 489 491 541 601 539 545 602 660
357 388 364 385 390 376 375 395 424 398 401 432 458
Operating Profit 142 109 121 118 144 113 116 146 178 141 145 170 202
OPM % 28% 22% 25% 23% 27% 23% 24% 27% 30% 26% 27% 28% 31%
14 12 12 8 9 10 14 14 18 18 18 21 22
Interest 5 9 12 8 11 9 9 8 8 7 7 6 6
Depreciation 20 31 38 36 39 38 38 35 36 36 37 35 35
Profit before tax 131 82 84 81 103 76 83 118 152 116 120 150 183
Tax % 26% 29% 26% 28% 30% 30% 32% 29% 27% 29% 28% 28% 29%
96 58 62 58 72 54 57 84 111 82 86 108 131
EPS in Rs 11.40 6.88 7.35 6.92 8.60 6.33 6.80 9.90 13.09 9.74 10.12 12.75 15.46
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
452 558 660 791 912 1,057 1,203 1,330 1,581 2,087 2,017 2,227 2,346
354 419 504 582 675 793 910 987 1,145 1,526 1,527 1,617 1,689
Operating Profit 98 139 156 210 238 264 294 344 436 561 490 609 658
OPM % 22% 25% 24% 26% 26% 25% 24% 26% 28% 27% 24% 27% 28%
3 8 12 20 27 31 46 55 51 52 42 69 79
Interest 0 0 0 0 1 1 1 15 16 30 38 29 26
Depreciation 20 27 28 28 28 33 38 73 77 108 150 144 143
Profit before tax 80 119 140 201 237 261 301 310 394 475 344 505 569
Tax % 31% 33% 31% 34% 34% 34% 33% 27% 25% 26% 30% 28%
55 80 96 133 156 172 200 228 296 350 241 362 407
EPS in Rs 1,643.22 148.27 17.51 15.99 18.61 20.49 23.90 27.11 34.99 41.37 28.65 42.85 48.07
Dividend Payout % 9% 7% 9% 15% 16% 22% 25% 44% 57% 29% 21% 42%
Compounded Sales Growth
10 Years: 15%
5 Years: 13%
3 Years: 12%
TTM: 11%
Compounded Profit Growth
10 Years: 16%
5 Years: 12%
3 Years: 7%
TTM: 33%
Stock Price CAGR
10 Years: %
5 Years: 14%
3 Years: -4%
1 Year: 12%
Return on Equity
10 Years: 23%
5 Years: 21%
3 Years: 20%
Last Year: 20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 3 54 55 83 83 83 83 83 83 83 83 83 84
Reserves 157 151 260 425 512 705 862 949 1,162 1,418 1,583 1,766 1,918
2 28 27 0 0 0 0 0 150 533 420 247 198
106 119 134 118 95 128 145 341 265 309 297 357 397
Total Liabilities 269 352 475 625 690 916 1,091 1,374 1,661 2,343 2,383 2,454 2,598
127 140 150 166 152 208 209 413 447 1,369 1,305 1,228 1,189
CWIP 1 0 1 4 18 10 3 11 10 15 5 6 1
Investments 55 9 38 64 106 145 185 164 59 65 150 114 289
87 203 286 391 414 554 694 786 1,144 893 923 1,107 1,119
Total Assets 269 352 475 625 690 916 1,091 1,374 1,661 2,343 2,383 2,454 2,598

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
88 98 122 159 171 197 219 284 398 447 456 535
-64 -89 -113 -163 -137 -172 -100 -26 -212 -449 -287 -24
-15 -10 -1 0 -32 13 -55 -190 -139 136 -283 -414
Net Cash Flow 9 -2 8 -5 2 37 64 67 48 134 -114 97

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 16 16 17 17 17 14 16 14 15 15 13 13
Inventory Days 37 31 33 44 40 70 39 38 28 30
Days Payable 90 89 97 106 111 144 132 107 127 151
Cash Conversion Cycle 16 16 -35 -42 -47 -47 -55 -60 -78 -54 -87 -108
Working Capital Days -39 -26 -9 27 19 17 0 -19 -17 -14 -19 -23
ROCE % 58% 60% 48% 47% 43% 38% 35% 32% 33% 29% 18% 25%

Shareholding Pattern

Numbers in percentages

57 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
55.23% 55.23% 55.05% 55.04% 55.04% 55.03% 55.01% 54.61% 54.60% 54.60% 54.60% 53.92%
25.45% 23.44% 22.37% 23.26% 25.80% 24.89% 23.27% 24.35% 25.36% 26.15% 25.43% 26.82%
6.57% 6.83% 6.52% 6.27% 6.20% 6.56% 8.34% 8.85% 9.27% 9.40% 12.42% 12.60%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.29% 0.29% 0.29% 0.29% 0.29% 0.29%
12.01% 13.80% 15.46% 14.84% 12.38% 13.01% 12.65% 11.48% 10.12% 9.24% 6.95% 6.02%
0.74% 0.70% 0.60% 0.58% 0.56% 0.51% 0.44% 0.41% 0.37% 0.32% 0.30% 0.33%
No. of Shareholders 1,35,0681,71,8461,84,5081,71,6021,79,6361,80,1631,74,4441,60,6791,49,9011,46,7411,31,1891,16,606

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls